RPL22 and cancer: Supplementary Figure 6b shows 26 nc-SCMs residing in cancer genes across 15 cancer types, namely, AKT2, ARAF, ARFRP1, ARID1B, ATP5B, BCOR, BUB1B, CDH1, CDKN1B, COL7A1, DNMT3A, EP300, ERBB3, ERCC2, FLCN, FUBP1, KMT2B, MALAT1, MAP3K1, MBD1, PBRM1, PTEN, RPL22, SMAD4, SMARCNB1, and TP53. We note that these expression outliers did not pass the FDR <0.05 cut-off; see “Methods.”